Various forms of mutant p53 confer sensitivity to cisplatin and doxorubicin in bladder cancer cells

Journal of Urology

Volumn 166, Issue 1, 2001, Pages 304-310

  Chang, Fu Lin ^b   Lai, Ming Derg ^b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NONE

Author keywords

Bladder; Bladder neoplasms; Cisplatin; Doxorubicin; Genes, p53

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; ANTINEOPLASTIC AGENT; CISPLATIN; DNA NUCLEOTIDYLEXOTRANSFERASE; DOXORUBICIN; LIPOCORTIN 5; MUTANT PROTEIN; PROTEIN P53; TRYPAN BLUE;

APOPTOSIS; ARTICLE; BLADDER CANCER; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0034978219     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)66150-2     Document Type: Article

References (26)

1. p53 Function and dysfunction
2. p53, the cellular gatekeeper for growth and division
3. p53: From inductive signal to cellular effect
4. p53 and apoptosis
5. p53 Mutations in human cancer
6. Clinical implications of the p53 tumor-suppressor gene
7. P53 mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents
8. Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: Spontaneously mutant selection
9. p53 Gene status modulates the chemosensitivity of non-small cell lung cancer cells
10. Apoptosis, p53, and tumor cell sensitivity to anticancer agents
11. p53 gene mutation, microsatellite instability and adjuvant chemotherapy: Impact on survival of 388 patients with Duke's C colon carcinoma
12. Patterns of p53 gene mutations in head and neck cancer: Full-length gene sequencing and results of primary radiotherapy
13. MVAC chemotherapy-induced apoptosis and p53 alterations in the rat model of bladder cancer
14. Accumulation of mutant p53 (V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status
15. Induction of apoptosis by the p53-273L (Arg-> Leu) mutant in HSC3 cells without transactivation of p21Waf1/Cip1/Sdi1 and bax
16. Increased apoptosis induction by 121F mutant p53
17. Inactivation of p53 in normal human cells increases G2/M arrest and sensitivity to DNA-damaging agents
18. Disruption of p53 in human cancer cells alters the responses to therapeutic agents
19. P53 and treatment of bladder cancer
20. Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions
21. Mutant p53 gain of function: Differential effects of different p53 mutants on resistance of cultured cells to chemotherapy
22. The relationship between p53 status and anticancer drugs-induced apoptosis in nine human bladder cancer cell lines
23. Antagonism of p53-dependent apoptosis by mitogen signals
24. Synergistic enhancement of resistance to cisplatin in human bladder cancer cells by overexpression of mutant-type p53 and Bcl-2
25. p53 Status affects the rate of the onset but not the over all extent of doxorubicin-induced cell death in rat-1fibroblasts constitutively expressing c-Myc
26. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations